[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100569096","lets-get-real-family-health-communication-tool-in-pediatric-stem-cell-transplant-and-cellular-therapy-100569096",false,"NCT06689800","Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Let's Get REAL: A Pilot Trial of a Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Inclusion Criteria Youth:\n\n* Children or adolescents 8-17 years of age referred for SCTCT.\n* Diagnosis of malignant or nonmalignant disorder.\n* Referred for any type of SCTCT. Autologous and allogeneic stem cell and cellular therapies are eligible.\n* Planning to meet with a provider to discuss SCTCT.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed assent document.\n* Must speak English and be cognitively able to participate.\n\nInclusion Criteria Parents:\n\n* Parent or guardian of a child 8-17 years of age with any diagnosis referred for any type of SCTCT. Diagnoses may include malignant and nonmalignant disorders. Autologous and allogeneic stem cell and cellular therapies are eligible. Parent or guardian is defined as an adult who usually cares for the youth and has authority to make medical decisions for them.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed consent document.\n* Must speak English and be cognitively able to participate.\n\nExclusion Criteria Youth:\n\n* Active medical problems severe enough to preclude study participation at the time of recruitment.\n\n  * Patients who are otherwise eligible, but whose primary transplant physician does not want them to participate in the study.\n* Lacks cognitive capacity to complete study activities, as determined by consenting professional.\n\nExclusion Criteria Parents:\n\n* Their youth referred for SCTCT does not assent to participate.","ALL","8 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasing youth involvement in real-time stem cell transplant and cellular therapy decisions (SCTCT). The investigators will pilot the intervention among 24 youth and their parents, stratified by youth age (stratum 1, 8-12 years of age and stratum 2, 13-17 years of age).",[26,27,28,29,30,31],"Hematologic Malignancy","Solid Tumor","Sickle Cell Disease","Aplastic Anemia","Immune Deficiency","Metabolic Disorder",[33,34,35,36,37],"Pediatric","Family","Decision making","Health Communication","Intervention","RECRUITING","2026-06-01",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":42},"2024-11-26",{"date":46,"type":20},"2026-11-30",{"name":48,"class":49},"Washington University School of Medicine","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100412703","rheopheresis-as-adjuvant-treatment-of-calciphylaxis-100412703","NCT04654000","Rheopheresis as Adjuvant Treatment of Calciphylaxis","Efficacy of Rheopheresis as Adjuvant Treatment of Calciphylaxis in Hemodialysis Patients : a Prospective Randomized Controled Single-blind Trial","RHEO-CAL","Inclusion Criteria:\n\n* Calciphylaxis with at least one ulcerated or necrotizing lesion\n* End stage renal disease requiring hemodialysis\n* Weight superior to 30kg\n* Subject affiliated to or beneficiary of a social security system\n* Subject having signed written informed consent\n\nA patient with progressing calciphylaxis to ulcerate or necrosis despite conventional treatment may also be included.\n\nExclusion Criteria:\n\n* KARNOFSKY Performance Status Scale inferior to 30%\n* Life expectancy (independently of calciphylaxis) estimated \\\u003C 6 months according to a referring physician expert in hemodialysis\n* Uncontrolled infection (persistence of fever despite appropriate antibiotic therapy)\n* Common variable immunodeficiency\n* Albumin allergy\n* Contra-indication to stop anti-vitamin K treatment\n* Severe cognitive or psychiatric disorders, patients unable to give an informed consent or unwilling to participate in the study\n* Pregnancy or breastfeeding and all the other categories of people with special protection according to the French Code de la Santé Publique (CSP): patients under legal supervision, patients hospitalized without contentment, patients admitted in social or sanitary structures for care and not research, and patients in emergency situations.","18 Years",{"count":61,"type":20},138,[23],"The investigators propose to set up a prospective randomized controlled trial to control the security and assess the efficacy of adjuvant treatment by rheopheresis in necrotizing-ulcered calciphylaxis in the hemodialysis population.",[31,65,66],"End Stage Renal Disease","Rare Diseases",[68,69,70,71],"Calciphylaxis","Rheopheresis","Hemodialysis","Chronic kidney disease","2026-02-09",{"date":74,"type":42},"2026-02-12",{"date":76,"type":42},"2023-03-07",{"date":78,"type":20},"2027-05",{"name":80,"class":49},"University Hospital, Lille",29]